2.05 USD
▼-0.04-2.15%
盘后 2.09 +1.95%
2026-09-15
市值
$117.62M
市盈率
—
EPS
-0.20
股息率
—
52 周区间
0.76 – 3.54
成交量
231.19K
Beta
1.80
目标价
8.56
52W 低 0.7652W 高 3.54
价格走势
公司简介
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its n...
关联新闻
- EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.